Abstract: An evaluation method is performed by an arithmetic circuit and includes obtainment processing (S1), evaluation processing (S2), and presentation processing (S3). The obtainment processing (S1) obtains: image information on a sectional image representing an interested section of an organism including a target section of a testis of the organism generated by use of magnetic resonance of hydrogen atoms; and concentration information on a creatine concentration in the interested section measured by use of magnetic resonance based on chemical exchange saturation transfer. The evaluation processing (S2) generates an evaluation image representing a distribution of evaluation results of a testicular function in the target section based on the concentration information. The presentation processing (S3) presents the sectional image and the evaluation image.

Abstract: A method of treating bradyarrhythmia includes administering to a patient having bradyarrhythmia a therapeutically effective amount of at least one of compound (I) and compound (II) or pharmacologically acceptable salts thereof as an active component: wherein Ph is a phenyl group.

Abstract: A therapeutic agent for drug-induced bradycardia and bradyarrhythmia. A therapeutic agent for drug-induced bradycardia and bradyarrhythmia including, as an active ingredient, the following compound (I): (wherein Ph is a phenyl group) or a pharmacologically acceptable salt of the compound.

Abstract: The object of the present invention is to provide a polynucleotide which can be inserted into an expression vector and can enhance the transcriptional activity of a predetermined promoter under heart failure. The object is achieved by an enhancer polynucleotide comprising a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 1, or a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 2, wherein the enhancer polynucleotide responds to heart failure (where the enhancer polynucleotide excludes a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 13 and a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 12).

Abstract: A therapeutic agent for bradyarrythmia contains the following compound (I) or compound (II) or a pharmacologically acceptable salt thereof as an active component: (wherein, Ph is a phenyl group).

Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: A complex essentially comprising a protein having an action of binding to a membrane-bound HB-EGF to promote the uptake of the membrane-bound HB-EGF by cells, and a carrier.

Abstract: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer particularly, metastatic cancer and angiogenic diseases.

Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Abstract: A specific strain of KK obese mice was found to show a phenotype peculiar to human arrythomogenic right ventricular dysplasia (ARVD), and Lamrl-functional transposon 1 (Lamr1-tp1) was determined to be responsible for this phenotype. Furthermore, the translation product of Lamr1-tp1 was shown to interact with HP1-alpha. Together with the knowledge that human ARVD loci are reported to exist close to the retroposons of Lamr1 or histone-modulating protein genes, aberrant interaction of mutant-LAMR1 and HP1-alpha seems to be a cause of ARVD. Thus, the present invention relates to methods for diagnosing ARVD. The present invention further relates to an animal model of ARVD, and cells transfected with mutant Lamr1 gene demonstrated to cause ARVD in the animal model. Moreover, the present invention relates to methods of screening for compounds suppressing ARVD using the animal model or the transfected cells.

Abstract: The present invention relates to VEGF receptors (VEGFR) and neuropilins such as VEGF165R/NP-1 and NP-2 that are associated with metastatic potential of a malignant cell and their use in the diagnosis and prognosis of cancer. Preferred ones are VEGF165R/NP-1 and NP-2 but any neuropilin or VEGFR, where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2 can be used. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

Abstract: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.